Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Hyun‐Soo Cho, Karen Mason, Kasra X. Ramyar et al. · Nature · 2003 · 1.6K citations

Life Sciences, Biochemistry, Molecular Biology +12

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Stephen Chia, Tamas Hickish, V. Harvey et al. · Annals of Oncology · 2013 · 1.3K citations

Medicine, Oncology, Pharmacology +14

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Matthew C. Franklin, Kendall D. Carey, F.F. Vajdos et al. · Cancer Cell · 2004 · 1.1K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +8